Sorrento Therapeutics (SRNE) Competitors

$0.0007 0.00 (-12.50%)

As of 03:45 PM Eastern

SRNE vs. UPC, ZVSA, IMCC, ITRM, and ABP

Should you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Universe Pharmaceuticals (UPC), ZyVersa Therapeutics (ZVSA), IM Cannabis (IMCC), Iterum Therapeutics (ITRM), and Abpro (ABP). These companies are all part of the "pharmaceutical products" industry.

How does Sorrento Therapeutics compare to Universe Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

: In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 1 mentions for Universe Pharmaceuticals and 0 mentions for Sorrento Therapeutics. Universe Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.
Company Overall Sentiment
Universe Pharmaceuticals Neutral
Sorrento Therapeutics Neutral
: Universe Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Universe Pharmaceuticals $17.86M 0.10 -$3.67M N/A N/A
Sorrento Therapeutics $60.32M 0.01 -$572.84M -$0.43 N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Sorrento Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Company Net Margins Return on Equity Return on Assets
Universe Pharmaceuticals N/A N/A N/A
Sorrento Therapeutics N/A N/A N/A
: 0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: Universe Pharmaceuticals has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
Sorrento Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.10	-$3.67M	N/A	N/A
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Sorrento Therapeutics	N/A	N/A	N/A

Summary

Universe Pharmaceuticals beats Sorrento Therapeutics on 7 of the 8 factors compared between the two stocks.

How does Sorrento Therapeutics compare to ZyVersa Therapeutics?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

: 3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: ZyVersa Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ZyVersa Therapeutics N/A N/A -$9.41M -$1.34 N/A
Sorrento Therapeutics $60.32M 0.01 -$572.84M -$0.43 N/A
: ZyVersa Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.
: Sorrento Therapeutics' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
ZyVersa Therapeutics N/A -109.54% -43.95%
Sorrento Therapeutics N/A N/A N/A
: In the previous week, ZyVersa Therapeutics had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 1 mentions for ZyVersa Therapeutics and 0 mentions for Sorrento Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.
Company Overall Sentiment
ZyVersa Therapeutics Neutral
Sorrento Therapeutics Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$1.34	N/A
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
Sorrento Therapeutics	N/A	N/A	N/A

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
Sorrento Therapeutics	Neutral

Summary

Sorrento Therapeutics beats ZyVersa Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Sorrento Therapeutics compare to IM Cannabis?

Sorrento Therapeutics (NASDAQ:SRNE) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
IM Cannabis
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: IM Cannabis has lower revenue, but higher earnings than Sorrento Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sorrento Therapeutics $60.32M 0.01 -$572.84M -$0.43 N/A
IM Cannabis $39.17M 0.04 -$8.10M -$1.41 N/A
: Sorrento Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500.
: Sorrento Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -21.24%. Sorrento Therapeutics' return on equity of 0.00% beat IM Cannabis' return on equity.
Company Net Margins Return on Equity Return on Assets
Sorrento Therapeutics N/A N/A N/A
IM Cannabis -21.24% -585.96% -28.74%
: In the previous week, IM Cannabis had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 1 mentions for IM Cannabis and 0 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score.
Company Overall Sentiment
Sorrento Therapeutics Neutral
IM Cannabis Neutral
: 0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A
IM Cannabis	$39.17M	0.04	-$8.10M	-$1.41	N/A

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
IM Cannabis	-21.24%	-585.96%	-28.74%

Company	Overall Sentiment
Sorrento Therapeutics	Neutral
IM Cannabis	Neutral

Summary

Sorrento Therapeutics beats IM Cannabis on 7 of the 13 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Iterum Therapeutics?

Sorrento Therapeutics (NASDAQ:SRNE) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

: 0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.
Company Overall Sentiment
Sorrento Therapeutics Neutral
Iterum Therapeutics Neutral
: Iterum Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sorrento Therapeutics $60.32M 0.01 -$572.84M -$0.43 N/A
Iterum Therapeutics $390K 4.10 -$24.77M -$0.75 N/A
: Iterum Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 29,900.00%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than Sorrento Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Iterum Therapeutics
1 Sell rating(s)

2 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.67
: Company Net Margins Return on Equity Return on Assets
Sorrento Therapeutics N/A N/A N/A
Iterum Therapeutics N/A N/A -65.54%
: Sorrento Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the S&P 500.

Company	Overall Sentiment
Sorrento Therapeutics	Neutral
Iterum Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
Iterum Therapeutics	N/A	N/A	-65.54%

Summary

Iterum Therapeutics beats Sorrento Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Abpro?

Abpro (NASDAQ:ABP) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

: Abpro has higher earnings, but lower revenue than Sorrento Therapeutics. Abpro is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abpro N/A N/A -$7.23M -$4.23 N/A
Sorrento Therapeutics $60.32M 0.01 -$572.84M -$0.43 N/A
: 23.3% of Abpro shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 13.7% of Abpro shares are owned by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Abpro's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.
Company Overall Sentiment
Abpro Neutral
Sorrento Therapeutics Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abpro
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50
Sorrento Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Company Net Margins Return on Equity Return on Assets
Abpro N/A N/A -344.76%
Sorrento Therapeutics N/A N/A N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A

Company	Overall Sentiment
Abpro	Neutral
Sorrento Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Sorrento Therapeutics	N/A	N/A	N/A

Summary

Abpro and Sorrento Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

Get Sorrento Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRNE vs. The Competition

Export

Metric	Sorrento Therapeutics	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$386K	$329.01M	$6.25B	$11.77B
Dividend Yield	N/A	N/A	2.74%	5.26%
P/E Ratio	0.00	N/A	29.25	27.07
Price / Sales	0.01	189.48	504.68	73.43
Price / Cash	N/A	22.44	43.30	53.90
Price / Book	N/A	4.73	9.67	6.69
Net Income	-$572.84M	-$132.96M	$3.55B	$332.64M
7 Day Performance	N/A	6.97%	1.70%	2.01%
1 Month Performance	N/A	4.03%	5.62%	9.19%
1 Year Performance	N/A	37.44%	34.42%	39.59%

Sorrento Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRNE Sorrento Therapeutics	N/A	$0.00 -12.5%	N/A	N/A	$386K	$60.32M	N/A	800	Upcoming Earnings Gap Down
UPC Universe Pharmaceuticals	0.1059 of 5 stars	$3.00 -1.6%	N/A	N/A	$1.68M	$17.86M	N/A	220	Gap Down
ZVSA ZyVersa Therapeutics	N/A	$0.21 -0.6%	N/A	N/A	$1.68M	N/A	N/A	2	Upcoming Earnings Gap Up
IMCC IM Cannabis	0.3095 of 5 stars	$0.26 -7.1%	N/A	N/A	$1.60M	$54.73M	N/A	340	Gap Up
ITRM Iterum Therapeutics	1.1617 of 5 stars	$0.03 flat	$9.00 +29,900.0%	N/A	$1.60M	$390K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRNE) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sorrento Therapeutics (SRNE) Competitors

SRNE vs. UPC, ZVSA, IMCC, ITRM, and ABP

How does Sorrento Therapeutics compare to Universe Pharmaceuticals?

Summary

How does Sorrento Therapeutics compare to ZyVersa Therapeutics?

Summary

How does Sorrento Therapeutics compare to IM Cannabis?

Summary

How does Sorrento Therapeutics compare to Iterum Therapeutics?

Summary

How does Sorrento Therapeutics compare to Abpro?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRNE vs. The Competition

Sorrento Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sorrento Therapeutics (SRNE) Competitors

SRNE vs. UPC, ZVSA, IMCC, ITRM, and ABP

How does Sorrento Therapeutics compare to Universe Pharmaceuticals?

Summary

How does Sorrento Therapeutics compare to ZyVersa Therapeutics?

Summary

How does Sorrento Therapeutics compare to IM Cannabis?

Summary

How does Sorrento Therapeutics compare to Iterum Therapeutics?

Summary

How does Sorrento Therapeutics compare to Abpro?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRNE vs. The Competition

Sorrento Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools